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Endolysosomal organelles play a key role in trafficking, breakdown and receptor-mediated
recycling of different macromolecules such as low-density lipoprotein (LDL)-cholesterol,
epithelial growth factor (EGF) or transferrin. Here we examine the role of two-pore channel
(TPC) 2, an endolysosomal cation channel, in these processes. Embryonic mouse fibroblasts
and hepatocytes lacking TPC2 display a profound impairment of LDL-cholesterol and
EGF/EGF-receptor trafficking. Mechanistically, both defects can be attributed to a dysfunction
of the endolysosomal degradation pathway most likely on the level of late endosome to
lysosome fusion. Importantly, endolysosomal acidification or lysosomal enzyme function are
normal in TPC2-deficient cells. TPC2-deficient mice are highly susceptible to hepatic
cholesterol overload and liver damage consistent with non-alcoholic fatty liver hepatitis.
These findings indicate reduced metabolic reserve of hepatic cholesterol handling. Our results
suggest that TPC2 plays a crucial role in trafficking in the endolysosomal degradation
pathway and, thus, is potentially involved in the homoeostatic control of many macro-
molecules and cell metabolites.
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E
ndo/lysosomal vesicle trafficking is important for many cells
and organ systems. In the liver, receptor-mediated uptake of
low-density lipoproteins (LDLs) and subsequent intra-
cellular transport is essential for hepatic cholesterol homoeostasis
and plasma lipoprotein metabolism. Dysfunction within this
pathway results in liver disease such as non-alcoholic fatty liver
disease (NAFLD), which is associated with increased cardio-
vascular and liver-related mortality1. NAFLD is the most
common cause of chronic liver disease in Western Europe and
the United States2,3. It has been estimated that as many as 30% of
adults in these countries have NAFLD2. This liver disease has
thus emerged as a substantial public health concern. The
spectrum of NAFLD ranges from simple lipid accumulation in
hepatocytes (steatosis) in absence of alcohol, which is considered
relatively benign, to steatosis with liver damage, inflammation
and fibrosis (non-alcoholic steatohepatitis (NASH)) and
progressive liver disease, including cirrhosis and hepatocellular
carcinoma4. The hallmark of NAFLD is hepatic neutral lipid
accumulation, mainly triacylglycerol and cholesterol ester (CE).
The roles of both triglycerides and free fatty acid accumulation in
NAFLD have been elucidated in many studies5. By contrast, the
role of cholesterol in NAFLD has been less extensively studied but
is gaining increasing attention1,6–8.
Recent studies have demonstrated that cholesterol metabolism
and trafficking might play an important role in the pathogenesis
of NAFLD and NASH1. Cholesterol is highly enriched in LDLs
and is taken up by the liver via receptor-mediated endocytosis of
the LDL–LDL receptor complex at the plasma membrane. After
internalization, membrane vesicles containing this complex fuse
to early endosomes. Subsequently, LDL receptors and its ligand
LDL are separated in the sorting endosome and distributed by
two major routes: the recycling pathway transports LDL receptor
proteins back to the plasma membrane; the degradation pathway
traffics LDL to late endosomes and lysosomes. This pathway
involves maturation of early endosomes into multivesicular
bodies/late endosomes which finally fuse with lysosomes9–15.
LDL-cholesterol exits from late endosomes and lysosomes and is
either metabolized to bile acids (BAs) and excreted, stored as CEs
in lipid droplets or exported from hepatocytes into the plasma.
While the principle pathways of LDL transport in the
endolysosomal vesicle system are well characterized, the distinct
proteins involved in these processes are largely unknown.
Interesting candidate proteins, which might regulate endolysoso-
mal trafficking, and fusion processes are cation channels present
in the membrane of endolysosomal vesicles. Recently identified
cation channels that may generate Ca2þ signals during
endolysosomal fusion events and thereby vesicle trafficking are
the two-pore channels (TPCs)16,17. Two different TPC subtypes
exist in mouse and man, TPC1 and TPC2. There is evidence
that TPC1 is mainly present in the proximal endosomal system,
and TPC2 is predominantly expressed on late endosomes and
lysosomes16,18,19. The activation mechanism of TPCs is complex
and has been suggested to involve the second messenger nicotinic
acid adenine dinucleotide phosphate (NAADP) and the
endolysosomal membrane lipidphosphatidylinositol (3,5)-
bisphosphate (PI(3,5)P2)17,18,20–24. Independent of what the
nature of the endogenous ligand of these channels might be,
there is substantial evidence that on activation TPCs mediate the
release of Ca2þ from lysosomal stores. Patch-clamp21,22,24, lipid
bilayer and calcium imaging experiments18,25,26 indicate that
TPCs are Ca2þ permeable channels and, hence, may directly
confer Ca2þ release from endosomes/lysosomes.
Here, we demonstrate that TPC2-deficient cells display
profound trafficking defects in the endolysosomal degradation
pathway. We provide evidence that TPC2 cation channels
may directly be involved in Ca2þ signalling necessary for
endolysosomal fusion processes. On the whole-animal level, we
demonstrate that loss of TPC2 leads, as a result of the observed
trafficking defects, to enhanced hepatic cholesterol accumulation,
hyperlipoproteinaemia, and to NASH. These findings indicate a
reduced metabolic reserve of hepatic cholesterol handling. Our
results suggest that TPC2 plays a crucial role in endolysosomal
trafficking in the endolysosmal degradation pathway and, thus, is
potentially involved in the homoeostatic control of many
macromolecules and cell metabolites.
Results
Loss of TPC2 impairs trafficking in the degradation pathway.
To test whether TPC2 is implicated in endolysosomal trafficking,
we disrupted the Tpc2 gene in the mouse (Fig. 1a). In this mouse
line, exon 7 of TPC2, which encodes TMD5 and part of the
pore-loop of domain I, is globally deleted (Fig. 1a). This targeting
strategy results in non-functional ion-channel proteins and is
different from the strategies used for two mouse lines published
before17,18. The deletion of the TPC2 gene was confirmed
by genomic DNA analysis using Southern blot (not shown),
PCR strategies, immunocytochemistry and western blotting
(Supplementary Fig. 1a,b). Reverse-transcription PCR (RT–PCR)
revealed the absence of exon 7 of TPC2 in TPC2 / murine
embryonic fibroblasts (MEFs) and hepatocytes (Supplementary
Fig. 1b). In addition, we generated a TPC2 antibody to detect
TPC2 protein. In agreement with the RT–PCR results,
TPC2 protein was totally absent in TPC2 / MEFs in
Figure 1 | Generation and characterization of TPC2 knockout mice. (a) Targeting strategy for the generation of TPC2 / mice and validation. The
targeted exon 7 of the mTPC2 gene encodes TMD5 and part of the pore-loop of domain I. Exons 6–8 are represented by boxes. The targeting vector
contains two loxP sites (green triangles), and a neo cassette flanked by two FLP recombination target (FRT) sites (blue triangles). (b) Representative
immunofluroscence (IF) images of WT and TPC2 / MEFs (stained with anti-TPC2 and Cy5) as well as WT and TPC2 / liver cryosections (stained
with anti-TPC2 and Alexa-488). Cell nuclei were visualized with Hoechst (MEFs) or 4’,6-diamidino-2-phenylindole (DAPI) (liver). Scale bars, 20 mm.
(c) Current–voltage relations of currents recorded from single-WT and -TPC2 / lysosomes in the presence of 50 nM NAADP or 10mM PI(3,5)P2.
Lysosomes were isolated from vacuolin-treated WT and TPC2 / MEFs before measurements. (d,e) Population data for current amplitudes at  200 mV
obtained from experiments as shown in a; **Po0.01, ***Po0.001, two-way analysis of varicane (ANOVA) followed by Bonferroni’s post hoc test (d) or
unpaired Student’s t-test (e). (f) Expression and distribution of selected marker proteins for endosomes and lysosomes were unaffected in TPC2 /
compared with WT MEFs. Shown are representative confocal images of WT and TPC2 / MEFs labelled with anti-EEA1, LAMP1 or LAMP2 and
Alexa-488. Nuclei were visualized with DAPI. Scale bar, 20mm. For additional markers, see Supplementary Fig. 1. (g) Representative electron microscope
images of WT and TPC2 / liver sections. BC, bile canaliculus; LY, lysosome; Mito, mitochondrion; RER, rough endoplasmic reticulum. Scale bars,
500 nm. (h,i) Measurement of endolysosomal pH in WTand TPC2 / cells. Late endocytic compartments of WT and TPC2 / MEFs were labelled with
dextran-Oregon Green 514. (h) Fluorescence intensity ratios were calculated for defined pH values as described in the Methods section. (i) Lysosomal
pH values in WT and TPC2 / MEFs were calculated using the calibration curves presented in h and determined under basal conditions, without amino
acids ( aa, EBSS), and without both, aa and glucose ( aa,  glc). Baf. A1 was used as positive control; n.s., not significant, unpaired Student’s t-test.
Data points in d,e,h and i are given as mean±s.e.m.
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immunocytochemistry experiments, while it could be detected
in wild-type (WT) MEFs (Fig. 1b). Western blot analysis of WT
and TPC2 / liver samples confirmed absence of TPC2 protein
in TPC2 / livers (Supplementary Fig. 1b). In lysosomes
prepared from TPC2 / MEFs, currents elicited by postulated
activators of TPC2, NAADP and PI(3,5)P2 were strongly reduced
(Fig. 1c–e). NAADP-dependent currents in WT lysosomes
displayed a bell-shaped dose-response relationship (Fig. 1d) as
reported previously25,26.
Expression and distribution of the early endosomal markers
EEA1, Rab4 and Rab5, the late endosomal/lysosomal markers
LAMP1, LAMP2, LIMP2 and CD63 or the recycling endosomal
markers TfR, Rab4 and Rab11 were comparable in WT
and TPC2 / cells (Fig. 1f and Supplementary Fig. 1c–e).
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Overexpression of the constitutively active Rab5 variant
Rab5(Q79L) induced the formation of characteristic enlarged
Rab5-positive vesicles both in WT and TPC2 / MEFs,
indicating that early endosomal fusion is functioning normally
(Supplementary Fig. 1f). Ultrastructural analyses of WT and
TPC2 / liver samples using electron microscopy revealed no
obvious alterations in the endolysosomal system (Fig. 1g). In
particular, the number of endolysosomal vesicles did not show
any deviations between the two genotypes. Notably, lysosomal
deposits which have been reported in lysosomal storage diseases
such as mucolipidosis type IV27,28 could not be detected in
TPC2 / mice.
Finally, steady-state endolysosomal pH values were similar in
TPC2 / and WT MEFs. This result was obtained in two
different, independently generated WT and TPC2 / batches
of MEFs: 5.08±0.1 for WT versus 4.93±0.06 for TPC2 /
(batch-1) and 4.87±0.03 for WT versus 4.89±0.02 for TPC2 /
(batch-2) (Fig. 1h,i and Supplementary Fig. 1g–i). Even under
starvation conditions (EBSS buffer ( aa) or starvation buffer
( aa/ glc)), no significant differences in endolysosomal
pH between WT and TPC2 / were observed (again two
independently generated MEF cell lines (batch-1 and batch-2)
were tested) (Fig. 1i and Supplementary Table 1). In addition, the
pH dependent, endolysosomal processing of cathepsin D and
cathepsin L was examined. In the acidic environments of late
endosomes and lysosomes, the mature forms of cathepsin D and
cathepsin L are produced after proteolytic removal of the
propeptide. We found that the generation of mature forms of
cathepsin D and L was not impaired in TPC2 / MEFs
compared with WT (Supplementary Fig. 1j). Specificity of the
detected bands was controlled by analysing lysates from the
respective cathepsin / MEFs in parallel.
Next, we assessed the functional consequences of a loss of
TPC2 for trafficking processes in the endolysosomal degradation
pathway (Fig. 2a), the main subcellular localization of TPC2. This
pathway can be tested by using labelled LDL which binds to its
receptor and is internalized into the cell via endocytosis10.
Subsequently, LDL dissociates from the receptor and is passed on
to late endosomes and lysosomes, from where cholesterol is
released into the cytosol (Fig. 2a). A trafficking or fusion defect
within this pathway would lead to accumulation of LDL in
vesicles proximal to the defect. We used LDL-BodipyFL to test
this hypothesis and found that the number of LDL-positive
vesicles per cell was significantly increased in TPC2 /
compared with WT MEFs (Fig. 2b–d). This effect was observed
at a broad range of LDL concentrations and after different pulse/
chase times (Fig. 2c,d). LDLR expression in WT and TPC2 /
MEFs was found to be similar as determined by quantitative
western blot experiments (normalized to glyceraldehyde
3-phosphate dehydrogenase) (Fig. 2e and Supplementary
Fig. 2a). As an independent test for the same pathway, we
performed experiments using labelled EGF (epithelial growth
factor; AlexaFluor488-EGF)29. These experiments revealed that
EGF accumulation is increased in TPC2 / compared with WT
MEFs (Fig. 2f–h). This finding was confirmed in independently
generated MEFs (batch-2) (Supplementary Fig. 2b,c). In addition,
in primary hepatocytes isolated from TPC2 / mice, the
number of EGF-positive vesicles per cell was also significantly
increased compared with WT hepatocytes, whereas EGFR
expression in WT and TPC2 / livers was not significantly
different (Fig. 2i and Supplementary Fig. 2d,e). To further assess
whether the increased accumulation was caused by decreased
degradation, the time course of EGF degradation after uptake was
measured. MEFs were incubated with a saturating concentration
of EGF (4 mg ml 1), followed by defined chase times before
fixation (Fig. 2j,k). In TPC2 / MEFs, the fluorescence
decreased significantly slower compared with WT MEFs.
To further determine the identity of the endolysosomal vesicles
where EGF accumulates in TPC2 / cells, we co-labelled cells
with markers for early endosomes (Rab5), late endosomes (Rab7),
and late endosomes/lysosomes (LAMP1), and found that about
57% of the EGF-positive vesicles showed co-labelling with Rab7
and 41% with LAMP1, but only about 5% with Rab5, indicating
that accumulation occurs rather in the late section of the
endolysosomal system than in early endosomes (Fig. 2l,m).
Taken together, these results suggested that EGF/EGFR and
LDL-cholesterol transport and degradation are impaired in
TPC2 / cells, and the endolysosomal transport machinery
appeared to be saturated significantly faster in TPC2 / than in
WT cells.
Calcium and TPC2 channels are critical for trafficking.
Endolysosomal trafficking defects can be caused by multiple
factors. They can result from defects in enzymatic degradation of
macromolecules, which is the underlying cause of most lysosomal
storage disorders. Impaired trafficking can also be caused by
defects in the acidification of endolysosomal organelles, defective
ionic homoeostasis or defects in endolysosomal fusion and fission
processes. Defects in acidification of endolysosomal vesicles have
been reported before to be the primary cause for the observed
trafficking abnormalities for example, in mucolipidosis type IV,
which is caused by mutations in the lysosomal cation channel
TRPML1 (refs 27,30,31). However, endolysosmal pH appears
normal in TPC2 / cells. Another attractive hypothesis for
impaired endolysosomal trafficking is a defect in vesicle fusion or
Figure 2 | TPC2 deletion leads to LDL and EGF/EGFR trafficking defects in the degradation pathway. (a) Cartoon illustrating endolysosomal degradation
and recycling pathways. In the degradation pathway (endo/lysosomal axis) EGF/EGFR and LDL are degraded. In the recycling pathway LDLR and Tf/TfR
are recycled. Cholesterol can exit the endolysosomal system from late endosomes or lysosomes. LE, late endosome; LY, lysosome; C, free cholesterol.
(b) Representative confocal images of WT and TPC2 / MEFs incubated with 3mg ml 1 LDL-BodipyFL. Cell nuclei were visualized with Hoechst.
(c) Average numbers of LDL-positive vesicles per cell after an incubation time of 30 min at concentrations as indicated. (d) Average numbers of LDL-
positive vesicles per cell after different incubation times at a concentration of 1 mg ml 1. (e) Quantitative western blot data showing average protein levels
of LDLR in WT and TPC2 / MEFs. (f) Representative confocal images of WT and TPC2 / MEFs incubated with 0.3 mg ml 1 AlexaFluor488-EGF.
(g) Average numbers of EGF-positive vesicles per cell after an incubation time of 30 min at concentrations as indicated. (h) Average numbers of
EGF-positive vesicles per cell after different incubation times at a concentration of 0.3mg ml 1, followed by a 2-h chase period. (i) Average numbers of
EGF-positive vesicles per cell from similar experiments with freshly prepared WT and TPC2 / hepatocytes. (j) Representative confocal images of
TPC2 / and WT MEFs incubated with 4mg AlexaFluor488-EGF for 30 min and chased for defined time intervals in EGF-free DMEM before fixation.
(k) Time course of EGF degradation obtained from experiments as shown in j. (l) Representative confocal images of WT and TPC2 / MEFs incubated
with 1mg ml 1 AlexaFluor488-EGF for 30 min, fixed and stained with anti-LAMP1, anti-Rab5 and anti-Rab7 antibody, respectively, and Cy5 as secondery
antibody. (m) Quantification of experiments as shown in l. All data points are given as mean±s.e.m. of at least three independent experiments, each.
At least two independently generated WT and TPC2 / MEF cell lines were analysed; n.s., not significant, ***Po0.001, **Po0.01, *Po0.05 (c,d,g,h and
k: two-way anlysis of variance (ANOVA) followed by Bonferroni’s post hoc test; e and i: unpaired Student’s t-test). All scale bars, 20mm.
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fission processes. It has been postulated before that Ca2þ is
required for vesicular fusion processes and thereby regulates
trafficking of vesicular cargo proteins30,32,33. In accordance
with this hypothesis, we found that in WT MEFs chelation of
cytosolic Ca2þ by 1,2-bis(2-aminophenoxy)ethane-N,N,N0,N0-
tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA-AM)
mimics the effect on EGF trafficking observed in TPC2 /
MEFs (Fig. 3a,b). This effect was dose dependent (Fig. 3a,b).
By contrast, in TPC2 / MEFs, EGF accumulation was not
significantly changed by BAPTA-AM (Fig. 3a,b). Ethyleneglycol-
bis(b-aminoethyl)-N,N,N0,N0-tetraacetoxymethyl ester (EGTA-
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Figure 3 | Effects of BAPTA-AM or TPC2 overexpression on endolysosomal trafficking in WT and TPC2 / MEFs. (a) Representative images of WT
and TPC2 / MEFs incubated with 0.1 mg ml 1 AlexaFluor488-EGF (5 min), followed by an incubation with 0.1 mg ml 1 AlexaFluor488-EGF in the
presence of either 0.03 mM or 0.3 mM BAPTA-AM (25 min) in PBS. Cell nuclei were visualized with Hoechst. Scale bar, 20mm. (b) Average numbers of
AlexaFluor488-EGF-positive vesicles per cell after incubation with BAPTA-AM at different concentrations as described in a. (c,d) Effect of 2 mM
bafilomycin A1 (Baf. A1; c) or 10mM nigericin (Nig.; d) on cytosolic calcium levels in WT and TPC2 / MEFs loaded with fura-2. Shown are representative
calcium imging experiments (mean of n¼ 10 cells, each). Measurements were performed in the presence of 2 mM EGTA. (e) Summary of Baf. A1 and
Nig. experiments; bars represent values 150 s (bafilomycin) or 450 s (nigericin) after compound application (n¼ at least five experiments with 5–10 cells,
each). (f) TPC2 WT, the inactive TPC2 mutant TPC2(N257A), or TRPML1 WT were fused to green fluorescent protein (GFP), overexpressed in TPC2 /
MEFs and incubated with 1mg ml 1 AlexaFluor555-EGF (red). Shown are representative images after fixation of the respective MEF cell line as indicated.
Cell nuclei were visualized with Hoechst. Scale bar, 20mm. (g) Average numbers of EGF-positive vesicles per cell taken from experiments as shown in e.
Non-transfected (NT) TPC2 / cells in close proximity to cells transfected with the respective cDNAs served as positive controls for each experiment.
All data points are given as mean±s.e.m. *Po0.05, **Po0.01, unpaired Student’s t-test.
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BAPTA-AM, had no significant effect on EGF accumulation
(Supplementary Fig. 2).
Bafilomycin A1 (Baf. A1)—a cell-permeant inhibitor of the
vacuolar-type Hþ -ATPase, results in loss of the lysosomal/late
endosomal proton gradient and eventually leads to the depletion
of luminal calcium34. By using Baf. A1 (in the absence of
extracellular calcium), we demonstrate that loss of TPC2
(TPC2 / MEF) causes a significant elevation in cytosolic
calcium compared with WT, suggesting that loss of TPC2 may
lead to an increased retention of calcium in the endolysosomal
lumen (Fig. 3c,e). Similar results were obtained when the
Kþ /Hþ exchanger nigericin was used instead of Baf. A1
(ref. 35) (Fig. 3d,e). Taken together, these results suggest that a
significantly higher amount of calcium is retained in intracellular
acidic compartments in TPC2 / compared with WT cells. To
confirm that the Ca2þ required for EGF trafficking depends on
the presence of TPC2, we performed rescue experiments in
TPC2 / MEFs and found that overexpression of WT TPC2 in
TPC2 / MEFs leads to a rescue of the EGF-trafficking defects
(Fig. 3f,g). The remaining EGF accumulation was not significantly
different from the amount of EGF accumulating in WT MEFs at
the respective EGF concentration (Fig. 2g). Notably, a non-
conducting TPC2 mutant (TPC2-N257A)21 was not sufficient to
rescue trafficking defects, suggesting that ion flux through TPC2
is necessary for the rescue. Furthermore, the rescue is specific for
TPC2 because TRPML1, another Ca2þ permeable and PI(3,5)P2-
activated cation channel in lysosomes36, did not rescue EGF-
trafficking defects observed in TPC2 / MEFs (Fig. 3f,g).
In vivo cholesterol accumulation in TPC2-deficient mice. Given
the pronounced impairments in LDL and EGF trafficking
observed in TPC2 / MEF cell lines and hepatocytes, we
hypothesized that defects might also be present in an in vivo
model. Therefore, WT and TPC2 / mice were fed with a
standard diet (SD) or a Western-type diet rich in cholesterol (CD)
for 6 weeks, respectively37. Analysis of TPC2 / mice fed with
SD indicated that these mice appeared identical to their WT
littermates as determined by morphological and histological
studies. The lack of a gross phenotype in TPC2 / mice on SD
is not surprising, since SD contains relatively little cholesterol
(r0.02% w/w). On this diet, the cholesterol requirement of the
animals is achieved primarily through de novo biosynthesis38.
We next tested the effect of a diet rich in cholesterol (1.25%
cholesterol; CD). The intake of cholesterol per day on this
diet is approximately 20–30 times above the amount an
average animal synthesizes to maintain homoeostasis when its
dietary needs are not being met38. The average liver weight/body
weight ratio of TPC2 / on CD was significantly increased
compared with WT on CD (Fig. 4a), while this parameter
was similar in WT and TPC2 / on SD. Importantly, there was
no difference in total body weight between the two groups of
mice, suggesting the absence of obesity in the TPC2 / mice.
On macroscopic examination, more than 95% (n¼ 21) of
TPC2 / livers (CD) displayed changes in colour ranging
from slightly yellow to strongly yellow (Fig. 4b,c). Only
about 5% of the livers looked normal. In contrast, 76% of WT
livers (CD) looked normal while 24% displayed a light yellow
colour (n¼ 21). Livers from WT and TPC2 / mice on SD did
not display visible changes in colour (n¼ 13 and n¼ 21,
respectively).
The prominent yellow colour of the livers from TPC2 /
mice on CD is highly suggestive for hepatosteatosis (fatty liver).
An analysis of the free and total hepatic cholesterol levels (free
cholesterol and CEs) revealed that in SD-fed WT and TPC2 /
mice, there was no difference in free and total liver cholesterol
levels (Fig. 5a–c). After CD treatment, free and total cholesterol
levels were elevated in both mouse lines. In TPC2 / mice,
cholesterol levels were significantly higher than in WT mice
(Fig. 5a–c). In particular, total cholesterol levels including
CEs were dramatically increased in TPC2 / liver samples
(Fig. 5a–c). In line with the biochemically observed hepatic
overload of cholesterol and CEs in TPC2 / mice on CD, liver
paraffin sections from TPC2 / mice on CD displayed strong
accumulation of lipid droplets of different sizes predominantly in
periportal hepatocytes (Fig. 5d). The histologic pattern is
consistent with/resembles non-alcoholic fatty liver disease which
is characterized by a microvesicular periportal hepatosteatosis.
Signs of periportal and pericellular fibrosis were seen in liver
sections from TPC2 / mice on CD (Fig. 5e). The strong
accumulation of lipid droplets was further confirmed by electron
microscopy of liver sections from TPC2 / mice on CD
compared with WT on CD (Fig. 5f). Filipin39–42 stainings further
confirmed a strong accumulation of cholesterol in TPC2 /
hepatocytes after CD treatment (Fig. 6a). A macroscopic analysis
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Figure 4 | Analysis of liver samples isolated from WT and TPC2 / mice. (a) Bar diagram showing average liver weight/body weight ratios (in %) of
WT and TPC2 / mice treated for 6 weeks with SD or CD, respectively. **Po0.01, two-way analysis of variance (ANOVA) followed by Bonferroni’s
post hoc test. (b) Shown are representative liver samples isolated from 10–12-week-old male WT and TPC2 / mice, treated with either SD or CD for six
consecutive weeks. Scale bar, 10 mm. (c) Pie charts showing the percentage of slightly to strongly yellow-stained liver samples isolated from WT and
TPC2 / mice treated with CD. Livers of SD-treated mice looked 100% normal.
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revealed the presence of large gallstones in TPC2 /
gallbladders (Supplementary Fig. 3a).
To test whether the severe cholesterol overload of TPC2 /
livers causes compensatory hepatic changes, a pathway analysis of
differentially regulated genes was performed in TPC2 /
and WT mice on SD and CD diet. This analysis revealed
significant enrichment of genes involved in lipid metabolism and
molecular transport (Supplementary Table 2). In line with an
increased hepatic pool of free cholesterol, transcriptional
upregulation of hepatic enzymes involved in BA and CE
synthesis as well as BA efflux was observed in TPC2 /
compared with WT mice on CD, while enzymes involved in
hepatic cholesterol synthesis were downregulated (Fig. 6b)43–45.









































































































































































































TPC2–/– CD Total cholesterol
Figure 5 | Hepatic cholesterol overload, liver damage and hyperlipoproteinaemia in TPC2 / mice. (a) Representative gas chromatogram (m/z
217þ 368) of total cholesterol and internal standard (IS) after alkaline hydrolysis in liver tissue prepared from male WT and TPC2 / mice on CD.
(b) Average hepatic levels of unesterified free cholesterol in male WT and TPC2 / mice on SD or CD as indicated (GC split ratio 3). (c) Average
total liver cholesterol levels, determined after alkaline ester hydrolysis (GC split ratio 15). (d) Representative images of liver paraffin sections of male WT
and TPC2 / mice on SD or CD diet, respectively, stained with haematoxylin–eosin (HE). BD, bile duct; PV, portal vein; CV, central vein. Scale bars,
100mm (SD left, CD left) and 20mm (SD right, CD right). White arrows point to some lipid droplets visible in CD WT sections. (e) Representative images
of liver paraffin sections stained with Sirius Red. PV, portal vein; CV, central vein. Scale bars, 100mm. Black arrows point to areas of pericellular fibrosis
in CD-treated TPC2 / livers. (f) Representative electron microscope images of WT and TPC2 / liver sections after CD treatment. Nu, nucleus;
scale bars, 5 mm. Data points in b and c are given as mean±s.e.m. (b and c: two-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test;
n.s., not significant, ***Po0.001.
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and TPC2 / mice on SD (data not shown), while a significant
downregulation was observed in livers from TPC2 / mice on
CD compared with WT on CD (Fig. 6b). Expression of the
ABC transporters ABCA1, ABCG5 (sterolin-1) and ABCG8
(sterolin-2) was not significantly upregulated (Fig. 6b). An
analysis of faecal BA content and composition revealed an
increase in BA excretion in CD compared with SD-fed animals,
which was, however, independent of the genotype
(Supplementary Fig. 3b). In liver, only one type of BA was
consistently detectable: cholic acid. While desoxycholic acid was
not detectable in liver samples of SD-fed animals, it was
detectable in 40% of the investigated CD-fed TPC2 /
animals (Supplementary Fig. 3c).
We further assessed functional hepatic consequences of the
measured cholesterol accumulation by determining liver-specific
enzyme levels in the peripheral blood. While no differences in
enzyme levels indicating liver damage such as glutamate
dehydrogenase or alanine transaminase were found in mice on
SD, significantly increased glutamate dehydrogenase and alanine
transaminase values (Fig. 6c and Table 1) were detected in
TPC2 / mice compared with WT on CD. Taken together,
























































































































































































































































Figure 6 | Cholesterol accumulation in liver tissue isolated from TPC2 / and WT mice and gene expression profile. (a) Representative images of
liver cryosections of WT and TPC2 / mice on CD diet, stained with filipin (0.05 mg ml 1 in PBS for 2 h) to visualize free cholesterol. Scale bars, 100mm
(left) and 20mm (right). (b) Relative expression (WT compared with TPC2 / on CD) of hepatic transcripts coding for proteins involved in: bile acid (BA)
synthesis (Cholesterol-7-alpha-hydroxylase, Cyp7a1), cholesterol synthesis (Acat1 (acetyl-CoA acetyltransferase 1, mitochondrial), Acat2 (acetyl-CoA
acetyltransferase 2, cytosolic), Hmgcr (HMG-CoA reductase), Cyp51 (Lanosterol 14a-demethylase), Tm7sf2 (delta(14)-sterol reductase), cholesterol ester
(CE) synthesis (Soat1 and Soat2 (sterol O-acyltransferase 1 and 2)), BA efflux (Abcc3 (canalicular multispecific organic anion transporter 2), Ostb (organic
solute transporter beta)), BA uptake (Slc10a1 (Naþ -taurocholate cotransporting polypeptide, Ntcp), Slco1a1 (organic anion-transporting polypeptide,
Oatp), sterol/cholesterol efflux transporters (Abca1, Abcg5, Abcg8) and cholesterol uptake (Ldlr). *Po0.05, **Po0.01, ***Po0.001, unpaired Student’s
t-test. Expression of Hmgcr and Ldlr was determined by quantitative RT–PCR and normalized to beta actin. (c) Average liver enzyme levels (GLDH
(glutamate dehydrogenase) and ALAT (alanine transaminase) in male WT and TPC2 / mice on SD or CD as indicated. (d) Average serum total
cholesterol levels in male WT and TPC2 / mice on SD or CD. (e) Average HDL-, LDL- and VLDL-cholesterol levels in serum of male WT and TPC2 /
mice on SD or CD diet. **Po0.01, ***Po0.001, two-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test; n.s., not significant.
(f) Cartoon illustrating hypothetical model of cholesterol accumulation. Cholesterol accumulates in LEs in TPC2 / cells due to a delay or impairment of
LE/LY fusion/trafficking processes (symbolized by the red flash); C, free cholesterol; CE, cholesterol ester; BA, bile acid. All data points are given as
mean±s.e.m.
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overload, liver damage was present in TPC2 / mice after CD
treatment.
Since the liver is the key organ in regulating lipoprotein
metabolism, we next determined systemic changes in lipopro-
teins. In WT and TPC2 / mice fed with SD, we found no
differences in total cholesterol as well as HDL- (high-density
lipoprotein), LDL- or VLDL-cholesterol (very low-density
lipoprotein cholesterol) plasma levels (Fig. 6d,e). However, in
mice on CD, total blood cholesterol levels as well as LDL- and
VLDL-cholesterol levels were strongly elevated. Notably, LDL-
and VLDL-cholesterol levels were significantly more increased in
TPC2 / than in WT mice. Serum HDL-cholesterol levels as
well as protein, triglyceride and glucose levels were similar within
both groups (Table 1). Finally, faecal total cholesterol levels were
increased in CD compared with SD-fed animals. However, here
no significant differences were detectable between the genotypes
(Supplementary Fig. 3d).
Discussion
Here, we show that TPC2 / mice are more susceptible to
cholesterol and CE accumulation in the liver than WT mice. This
accumulation is not caused by extrahepatic factors, because
similar accumulation is seen in single-cell experiments. The
macroscopic and histological presentation of TPC2 / livers,
the increased cholesterol accumulation and increase in hepatic
transaminases indicate fatty liver and liver damage, and are
consistent with the clinical picture of NAFLD and NASH.
The clinical phenotype can be explained by specific defects in
vesicle trafficking along the endolysosomal degradation pathway
in the TPC2 / mouse. In the absence of TPC2, receptors and
cargoes such as LDL or EGF/EGFR, which are transported along
the degradation pathway, accumulate rapidly in intracellular
vesicles of TPC2 / but not WT cells. This finding suggests that
TPC2 channels are critically involved in the regulation of
endolysosomal trafficking along this pathway. Since TPC2
channels are specifically expressed on late endosomes and
lysosomes, it is likely that TPC2 regulates or enhances the final
transport or fusion step between these two organelles. Consistent
with this hypothesis, deletion of TPC2 leads to a partial block in
transport and accumulation of LDL-cholesterol and LDL CEs
proximal to the fusion defect in the prelysosomal vesicle pool, in
particular late endosomes (Fig. 6f). LDL-derived CEs are
normally hydrolysed to free cholesterol by lysosomal and late
endosomal acid lipase and subsequently exported from the
endolysosomal system. Due to prelysosomal accumulation, more
cholesterol may exit via late endosomes in TPC2 / mice and
thus increase the free cholesterol pool in the cytosol. It is well
known that an increased free cholesterol pool at the endoplasmic
reticulum (ER) induces CE formation and deposition in lipid
droplets as well as downregulation of endogenous cholesterol
synthesis (Fig. 6f)43,44. In line with this theory, we found that CEs
are increased in TPC2 / mice. CEs are generated from free
cholesterol by Soat1 and Soat2 (sterol O-acyltransferase 1 and 2).
These enzymes are upregulated in livers of TPC2 / mice. ER
enzymes involved in endogenous cholesterol synthesis are
downregulated. Finally, serum VLDL levels are elevated in
TPC2 / mice on CD (Fig. 6e). While this elevation could be
caused by an increase in hepatic VLDL production, the possibility
of a reduced VLDL clearance cannot completely be ruled out.
Together, these results indicate that in TPC2 / hepatocytes,
secondary ER-dependent processes are induced. This could either
be caused by a globally increased free cholesterol pool or
alternatively by misrouting of free cholesterol to the ER. Such a
misrouting effect could be caused by a decreased flux of
cholesterol from late endosomes to lysosomes with an upregula-
tion of alternative trafficking pathways from late endosomes to
the ER. In support of this notion, there is increasing evidence of
contact sites between late endosomes and the ER46–48, as well as
evidence for direct vesicular and non-vesicular transport of
cholesterol to the ER from late endosomes49,50.
How could a proposed role of TPC2 for vesicular trafficking
and fusion be explained mechanistically? We demonstrate that in
MEFs, TPC2 is critically involved in the generation of a current
specifically activated by the known TPC2 activators NAADP and
PI(3,5)P2. It has been shown that PI(3,5)P2 concentrations
increase from early to late endosomes9,11,15. Thus, in the
absence or in the presence of very low levels of PI(3,5)P2, TPC2
may conduct only very small currents and progressively start to
open on maturation toward late endosomes as PI(3,5)P2 gradually
rises. Opening of TPC2 channels in late endosomes could initiate
the final fusion between late endosomes and lysosomes. Here, we
demonstrate that vesicle trafficking in the endo/lysosomal
degradation pathway requires Ca2þ and ion flux through
TPC2. The most likely interpretation is that Ca2þ flows
directly through TPC2 channels. TPC2 has been shown
previously to conduct Ca2þ (refs 18,21,22,24) and we confirm
here that endogenous TPC2 channels are permeable to calcium
(Supplementary Fig. 4). Opening of TPC2 channels may lead to
Ca2þ efflux from vesicles directly into microdomains
surrounding Ca2þ -dependent proteins of the fusion machinery
and thereby induce fusion. Anchoring of TPC2 within the cellular
fusion machinery is supported by interactions with specific
SNARE proteins such as STX7 and additional protein
components of SNARE complexes which were identified by
proteomics-based interaction screens, and confirmed by
fluorescence resonance energy transfer analyses and co-
immunoprecipitation experiments (Supplementary Fig. 5a–g
Table 1 | Summary of serum parameters.
WT SD TPC2 / s.d. ANOVA WT CD TPC2 / CD ANOVA
Mean±s.e.m. Mean±s.e.m. Mean±s.e.m. Mean±s.e.m.
Total cholesterol (mg dl 1) 78±5.8 72.0±5.7 n.s. 139.5±9.6 210.3±18.0 ***
GLDH (U l 1) 14.9±2.8 17.1±2.9 n.s. 32.3±4.8 49.4±5.0 *
ALAT (U l 1) 33.7±9.6 44.9±11 n.s. 34.9±8.4 60.8±7.7 *
ASAT (U l 1) 145.3±34 199.4±6.7 n.s. 118.6±23 155.4±34.5 n.s.
Total protein (g dl 1) 4.4±0.2 4.1±0.2 n.s. 4.4±0.1 4.2±0.2 n.s.
Glucose (mg dl 1) 163.9±12.0 170.7±12.0 n.s. 186.7±14.0 183.2±16.9 n.s.
Triglycerides (mg dl 1) 42.1±3.4 41.1±6.8 n.s. 33.8±2.9 28.3±5.0 n.s.
ANOVA, analysis of variance; ALAT, alanine transaminase; ASAT, aspartate transaminase; CD, cholesterol; GLDH, glutamate dehydrogenase; n.s. not significant; SD, standard diet; TPC, two-pore channel;
WT, wild type.
Table summarizing data shown in Fig. 6 c,d and additional serum parameters in WT and TPC2 / mice on SD and CD. Values are given as mean±s.e.m. (two-way ANOVA followed by Bonferroni’s post
hoc test, *Po0.05, ***Po0.001).
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and Supplementary Table 3)51–53. Alternatively, ionic flux
through TPC2 channels could also be part of an indirect
mechanism which provides Ca2þ . In this scenario, cations
other than Ca2þ flowing through TPC2 would act on a
downstream channel, which in turn provides Ca2þ . Naþ and
Kþ have also been shown to permeate through TPC2
channels17,20. Given the proposed close structural assembly of
TPCs and the fusion machinery (Supplementary Fig. 5g),
depolarization by Naþ efflux through TPC2 may also
electrostatically facilitate fusion between two vesicular
membranes as suggested by the model of Wang et al.17 Similar
events may be relevant for TPC1 within the proximal endosomal
pathway.
Defects in the endolysosomal trafficking and cellular proces-
sing of LDL-cholesterol have been implicated in human diseases
such as Niemann Pick disease and Wolman’s disease (CE storage
disease) where CEs accumulate in late endosomes and lysosomes
due to a severely diminished activity of cholesterol export
proteins NPC1 and NPC2 or lysosomal acid lipase54. Here, we
demonstrate that loss of TPC2 results in a defect which is more
distally located in the endolysosomal LDL-cholesterol trafficking
pathway. Loss of TPC2 increases the risk of developing NAFLD
and NASH. These diseases themselves are independent of
traditional cardiovascular risk factors and the metabolic
syndrome associated with increased risk for cardiovascular
disease. Furthermore, in obese individuals these diseases are
markers of insulin resistance and diabetes. Notably, TPC2 /
mice are highly susceptible to NAFLD and NASH, while obesity
and impaired glucose tolerance are not observed. This finding
suggests that TPC2 / mice have a reduced metabolic reserve in
hepatic cholesterol handling, which leads to NAFLD even in the
absence of obesity and impaired glucose tolerance. The increased
susceptibility of TPC2 / mice to NAFLD is clinically highly
relevant because this disease affects up to one-third of the
population worldwide and may cause adverse cardiovascular
outcome and increased cardiovascular mortality.
Methods
Generation of TPC2 / knockout mice. TPC2 / mice were generated by
deleting exon 7 and introducing an early stop codon. We generated a targeting
vector that, after homologous recombination, resulted in a modified TPC2 allele
carrying two loxP sites flanking exon 7. A neoR cassette, which was used for
G418/geneticin selection, was removed with Flp recombinase before the ES cells
were injected into host blastocysts to generate chimeric mice. After germline
transmission and continued breeding, PCR with genomic DNA from progeny of
WT, heterozygous and homozygous animals showed proper recombination and
inheritance of the TPC2lox allele. Subsequently, exon 7 was deleted by pairing
TPC2lox mice with mice expressing Cre-recombinase under a cytomegalovirus
promoter. Exon 7 encodes TMD5 and part of the pore-loop in domain I of TPC2.
Animals were used under approved animal protocols and University of Munich
(LMU) Institutional Animal Care Guidelines.
Whole-lysosome planar patch-clamp experiments. For whole-lysosome planar
patch-clamp recordings, isolated intact lysosomes from HEK293 cells or MEFs
were prepared by differential centrifugation as described previously21,22,55.
HEK293 cells stably expressing murine TPC2 or the TPC2 mutant TPC2(N257A),
both N-terminally fused to green fluorescent protein and subcloned into
pcDNA5FRT vector with hygromycin resistance (Invitrogen) were used. To
investigate STX7 effects on TPC2, a double stable HEK293 cell line was generated
coexpressing murine STX7, N-terminally fused to mCherry (in pcDNA3 vector
with geneticin (G418) resistance) and TPC2 as described above. The planar patch-
clamp technology combined with a fast internal perfusion system (Port-a-Patch,
Nanion Technologies) was applied as described previously21,22,55. Currents were
recorded using an EPC-10 patch-clamp amplifier and PatchMaster acquisition
software (HEKA). Data were digitized at 40 kHz and filtered at 2.8 kHz. Mean
endolysosomal capacitance was 1.01±0.04 pF (n¼ 47). For all experiments,
salt-agar bridges were used to connect the reference Ag-AgCl wire to the bath
solution to minimize voltage offsets. Unless otherwise stated, cytoplasmic solution
contained 60 mM KF, 70 mM K-MSA (methanesulfonate), 0.2 mM Ca-MSA, 4 mM
Na-MSA, 10 mM HEPES (pH adjusted with KOH to 7.2). Luminal solution was
60 mM Ca-MSA, 85 mM Na-MSA, 1 mM MgCl2, 10 mM HEPES (pH adjusted
with NaOH to 4.6 (refs 17,20)). Mannitol was used to adjust osmolarity.
For the application of PI(3,5)P2 (A.G. Scientific) or NAADP (Tocris Bioscience),
cytoplasmic solution was completely exchanged by PI(3,5)P2- or NAADP-
containing solution.
Endolysosomal trafficking experiments. For trafficking experiments,
AlexaFluor488-EGF, AlexaFluor555-EGF or LDL-BodipyFL (Life Technologies)
were used. MEFs from WT and TPC2 / mice were seeded on glass coverslips in
24-well plates and grown in Dulbeccos modified eagles medium (DMEM) with
10% fetal bovine serum at 37 C and 5% CO2 for 48 h. Cells were treated with
varying concentrations of labelled LDL or EGF and incubated for different time
intervals at 37 C and 5% CO2. Cells were subsequently washed in DMEM
containing no fetal bovine serum and fixed with ice-cold methanol for 5 min at
 20 C or chased before fixation for defined time intervals at 37 C and 5% CO2 in
DMEM containing no fetal bovine serum, as indicated in the respective figure
legends. Hoechst nuclear staining (Hoechst 33342) was performed in PBS buffer
(5 mg ml 1). Cells were incubated at room temperature for another 30 min, washed
twice with PBS and embedded in Cell Lab Fluoromount-G Slide Mounting
Medium (Beckman Coulter). In the degradation format, cells were incubated as
described above with a saturating concentration of AlexaFluor488-EGF
(4 mg ml 1) for 30 min, washed and incubated for different chase times as
indicated. For data quantification, ImageJ software was used. In each experiment,
numbers were calculated based on the total number of vesicles (dots) per image
divided by the number of cells (nuclei) per image. The term ‘cell’ is used instead of
‘confocal cell section’.
Endolysosomal pH measurements. Endolysosomal pH measurements were
performed by ratiometric fluorescence imaging as described previously56. MEFs
were seeded on imaging dishes (145 mm glass bottom, PAA Laboratories, Germany)
and grown overnight in DMEM supplemented with 1 g l 1 bovine serum albumin
in the presence of 500mg ml 1 of the pH-sensitive fluorophore Oregon Green 514
conjugated to dextran (70,000 MW, Life Technologies). In order to allow clearance
of early endocytic compartments and ensure specific localization of the dye in the
late endocytic pathway, cells were chased in DMEM at 37 C for 1 h in the presence
of bovine serum albumin followed by 1-h incubation in serum-free medium before
imaging for basal pH determination. To assess lysosomal pH under starvation
conditions, the chase procedure was replaced by either 2-h incubation without
amino acids (EBSS) or 2-h incubation without both, amino acids and glucose
(110 mM NaCl, 45 mM NaHCO3, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2,
pH 7.4)20. As a control for increased lysosomal pH, 200 nM Baf. A1 (Sigma
Aldrich) were applied during the 1-h incubation in serum-free medium under basal
conditions. Ratiometric imaging was performed using an Olympus FV1000
confocal laser scanning microscope. Cells were excited alternately by light
transmitted from a 440-nm laser diode or a multiline argon laser at 488 nm (Showa
electronics model GLS3135). In both cases, images were acquired at an emission
wavelength of 535±20 nm using a charge-coupled device-camera. At the end of
every experiment, an in situ calibration was performed for each genotype by
incubating the cells with isotonic Kþ buffer solutions (145 mM KCl, 10 mM
glucose, 1 mM MgCl2 and 20 mM of either HEPES, MES or acetate, pH ranging
from 4.0 to 7.0), containing 10 mg ml 1 of the ionophorenigericin. The resulting
fluorescence intensity ratios (488/440) were fitted to the Boltzmann equation to
interpolate pH values from the experimental ratio data.
Calcium imaging experiments. Calcium imaging experiments were performed
using fura-2 as described previously57. Briefly, WT and TPC2 / MEFs cells were
plated onto glass coverslips, and after 24 h, cells were loaded for 1 h with the
fluorescent indicator fura-2-AM (4 mM; Invitrogen) in a standard bath solution
containing (in mM) 138 NaCl, 6 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES and 5.5
D-glucose (adjusted to pH 7.4 with NaOH). Cells were washed in 2 mM EGTA for
30 min before measurement. Calcium imaging was performed using a
monochromator-based imaging system (Polychrome IV monochromator, TILL
Photonics). Compounds were applied in the presence of 2 mM EGTA.
Immunocyto- and immunohistochemistry, electron microscopy.
Immunocytochemistry was performed as described previously58. Histology,
immunohistochemistry and electron microscopy experiments were performed
according to standard protocols. For further details, please refer to Supplementary
methods.
Serum cholesterol levels and expression profiling in liver. Male TPC2 / and
WT mice were fed with standard chow diet (SD) or a high-cholesterol containing
Western-type diet (1.25% cholesterol, 15% fat, 0.5% Na-cholate; ssniff GmbH,
Soest, Germany) for 6 weeks. Throughout the text, we refer to this diet by calling it
cholesterol diet or CD. On the day of euthanasia, food was removed from the cage
and approximately 8 h later, mice were killed as described59 and blood was drawn
by left-ventricular puncture in EDTA-containing syringes. Cell counting was
performed after 1:4 dilution with PBS in an automated hematology analyzer
(Sysmex). Lipoproteins were isolated by sequential ultracentrifugation from 60 ml
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of plasma at do1.006 g ml 1 (VLDL) 1.006rdr1.063 g ml 1 (intermediate- and
low-density lipoprotein (IDL and LDL, respectively)) and d41.063 g ml 1 (high-
density lipoprotein (HDL)) in a TL100 ultracentrifuge (Beckman). Cholesterol was
determined enzymatically by using a colorimetric method (Roche).
RNA from liver samples of TPC2 / and WT mice fed with SD (WT n¼ 4;
TPC2 / n¼ 4) or CD (WT n¼ 4; TPC2 / n¼ 4) was isolated as described
previously60. RNA was labelled and hybridized to Illumina Mouse Ref-8 v2.0
Expression Bead Chips and arrays were scanned with an Illumina iScan microarray
scanner. Bead level data pre-processing was done in Illumina Genome Studio
followed by quantile normalization and background reduction according to
standard procedures in the software. Of the 425,600 annotated RefSeq transcripts
that were covered by the arrays, a total of 4,598 transcripts were upregulated or
downregulated in TPC2 / mice with fold changes 420% compared with
WT control. Of these, 2,159 transcripts were differentially regulated in livers of
mice on SD and 3,288 partially overlapping transcripts were differentially regulated
in livers of mice on CD. Using the Ingenuity Pathways Analysis software
(www.ingenuity.com), most significantly enriched biological functions in WT and
TPC2 / mice were identified and levels of significance were determined using
Fisher’s exact tests implemented in the software61. Alternatively, expression of Ldlr
(50-primer 50-TGGGTCATCGCCCTGCT-30 , 30-primer 50-TTCCTGCTGCATGA
GTCTTCT-30, probe 50FAM-50-CTGGCTGCTGCCGGAGTTGCA-30TAMRA),
Egfr (50-primer 50-CCTATGCCACGCCAACTGTAC-30, 30-primer 50-GATGGCC
ACACTTCACATCCT-30 , probe 50FAM-50-TATGGATGTGCTGGGCCAGGTC
TTC-30TAMRA) was assessed in liver samples by quantitative RT–PCR and
normalized to glyceraldehyde 3-phosphate dehydrogenase (50-primer 50-TGTCCG
TCGTGGATCTGACG-30 , 30-primer 50-CCAAGATGCCCTTCAGTGGG-30 ,
probe 50FAM-50-CGCCTGGAGAAACCTGCCAAGTATGATGAC-30TAMRA).
Determination of hepatic cholesterol by gas chromatography mass
spectrometry. Gas chromatography mass spectrometry analysis was performed
on a Varian 3800 gas chromatograph coupled with a Varian Saturn 2200 ion trap.
The stationary phase was an Agilent VF-5 ms capillary column with 30 m 0.25
mm inner diameter and 0.25 mm film thickness. The mobile phase was helium at a
constant flow rate of 1.4 ml min 1. The inlet temperature was 250 C, injection
volume 1 ml (split ratio 3 for free liver cholesterol and 15 for total liver cholesterol
after alkaline ester hydrolysis). The GC oven started at 70 C, ramped up to 270 C
(heating rate 50 C min 1), followed by a gradient of 5 C min 1 up to 310 C.
Transfer line temperature was 270 C and the ion-trap temperature was 200 C. MS
scanned from 8.5 to 12.0 min at a mass range of 100–550 m/z (electron ionization,
70 eV). The peak areas of characteristic ions forcholesterol tetramethylsilane ether
(368 m/z) and for cholestane (217 m/z) were used for data analysis. The mean value
of each double-injected sample (n¼ 5) was used for statistical analysis. For details
of sample preparation, please refer to Supplementary methods.
Statistical analysis. Details of statistical analyses and n values are provided in
the methods subsections or the figure legends. Statistical analyses were carried
out using Origin 7.5 and GraphPad Prism 5. All error bars are depicted as
mean±s.e.m. Statistical significance was determined via Student’s t-test, one-way
analysis of variance followed by Tukey’s post test, or two-way analysis of variance
followed by Bonferroni’s post hoc test, unless stated otherwise. Significance is
denoted on figures as outlined in the legends. Statistics were derived from at least
three independent experiments.
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57. Grimm, C., Jörs, S., Guo, Z., Obukhov, A. G. & Heller, S. Constitutive activity of
TRPML2 and TRPML3 channels versus activation by low extracellular sodium
and small molecules. J. Biol. Chem. 287, 22701–22708 (2012).
58. Schröder, J. et al. Deficiency of the tetraspanin CD63 associated with kidney
pathology but normal lysosomal function. Mol. Cell Biol. 29, 1083–1094 (2009).
59. Teupser, D., Persky, A. D. & Breslow, J. L. Induction of atherosclerosis by
low-fat, semisynthetic diets in LDL receptor-deficient C57BL/6J and FVB/NJ
mice: comparison of lesions of the aortic root, brachiocephalic artery, and
whole aorta (en face measurement). Arterioscler. Thromb. Vasc. Biol. 23,
1907–1913 (2003).
60. Holdt, L. M., Thiery, J., Breslow, J. L. & Teupser, D. Increased ADAM17 mRNA
expression and activity is associated with atherosclerosis resistance in LDL-
receptor deficient mice. Arterioscler. Thromb. Vasc. Biol. 28, 1097–1103 (2008).
61. Holdt, L. M. et al. Alu elements in ANRIL non-coding RNA at chromosome
9p21 modulate atherogenic cell functions through trans-regulation of gene
networks. PLoS Genet. 9, e1003588 (2013).
Acknowledgements
We thank Phuong Nguyen, Maximiliane Geerds, Berit Noack and Elisabeth Schulze
(LMU Munich) for technical support. CathL / MEFs were provided by Dr Thomas
Reinheckel (Institute of Molecular Medicine and Cell Research, Freiburg). Anti-LIMP2
antibody was provided by Dr Michael Schwake (Institute of Chemistry, Biochemistry III,
Bielefeld). Mice expressing Cre-recombinase under a cytomegalovirus promoter were
kindly provided by Professor Dr Freichel, Heidelberg. We further thank Professor
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